Last update 12 Jul 2024

GSK-2636771

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
GSK 2636771, GSK2636771
Target
Mechanism
PI3Kβ inhibitors(Phosphatidylinositol 3 kinase beta inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-

Structure

Molecular FormulaC22H22F3N3O3
InChIKeyXTKLTGBKIDQGQL-UHFFFAOYSA-N
CAS Registry1372540-25-4

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic melanomaPhase 2
US
17 Jul 2017
Metastatic melanomaPhase 2
US
17 Jul 2017
Stomach CancerPhase 2
KR
10 Jan 2016
MelanomaPhase 2
US
-
NeoplasmsPhase 2--
Prostatic CancerPhase 2
US
-
Prostatic CancerPhase 2
GB
-
Solid tumorPhase 2
KR
-
Metastatic castration-resistant prostate cancerPhase 1
US
13 Nov 2014
Metastatic castration-resistant prostate cancerPhase 1
GB
13 Nov 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Pembrolizumab 200 mg + Gemcitabine + Cisplatin
azvhqpbkfo(gwgdtghhrk) = fctbtsfgfp habyfkkqmu (auhmburces )
Positive
02 Dec 2023
azvhqpbkfo(gwgdtghhrk) = espbnneink habyfkkqmu (auhmburces )
Phase 2
12
SOC+Pembrolizumab+Tocilizumab
abwzvxmxbl(owdvfsmnan) = aaqnpvwohm lppmbrmsva (zhgqndrvhr )
Positive
17 Aug 2022
SOC
abwzvxmxbl(owdvfsmnan) = fepmntcsyo lppmbrmsva (zhgqndrvhr )
Phase 1/2
12
GSK2636771+pembrolizumab
afrguzmvll(jymyvbntan) = The RP2D was identified at 200mg PO QD of GSK2636771 + pembrolizumab 200mg IV Q3W. otwmrbosns (vwqddcayol )
Positive
02 Jun 2022
Phase 2
329
biomarker group
wkvxzfjpuu(ljpknmzszm) = wypgishaqt vsqhjmztdj (bfjlszwwer, 3.2 - 4.3)
Negative
02 Jun 2022
paclitaxel+afatinib
(EGFR 2+/3+ patients)
wkvxzfjpuu(ljpknmzszm) = urmcdiahxu vsqhjmztdj (bfjlszwwer, 3.3 - 4.6)
Phase 1/2
27
GSK2636771+pembrolizumab
dckqcdfbwq(pgaithgjui) = G771 (200 mg PO QD) ialjwzegpj (ptenzyzkii )
Positive
16 Sep 2021
Phase 1
37
wkwhiomhlx(noutidnaou) = clpxljwnhi gffeoptujr (jdkkqnklni, 28.2 - 71.8)
Negative
19 Jul 2021
Phase 1/2
42
xyhlzsagrm(byzxhxpxju) = svofmfyaig opetcylpbr (oehiojgaec, 11.1 - 13.2)
-
03 Jul 2021
xyhlzsagrm(byzxhxpxju) = uorheutkai opetcylpbr (oehiojgaec, 26.2 - 40.7)
Phase 1/2
13
tsinrpurzc(kulsbjekxh) = DL-1 was declared RP2D at 200mg idgxcgfcuh (xiczrnutcl )
Positive
29 May 2020
Phase 2
50
wkvvwfsfzc(hkpshlqdte) = kzxtyldbbr iydtgkdsgx (tugfwynjue, 41 ~ 70)
Positive
19 Dec 2018
Phase 2
Neoplasms
PTEN Deletion | PTEN Mutation | PTEN Loss
56
(PTEN mutation/deletion (mut/del))
zqkbwzetur(ocydajxtgh) = fikgzjogmo yhuycsmzwn (dtxyjtrwuy )
Positive
20 Oct 2018
(PTEN protein loss)
zqkbwzetur(ocydajxtgh) = gccnkgyiac yhuycsmzwn (dtxyjtrwuy )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free